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Abstract
The lack of standardized reporting of the magnitude of ischemia on noninvasive imaging
contributes to variability in translating the severity of ischemia across stress imaging modalities.
We identified the risk of coronary artery disease (CAD) death or myocardial infarction (MI)
associated with ≥10% ischemic myocardium on stress nuclear imaging as the risk threshold for
stress echocardiography and cardiac magnetic resonance. A narrative review revealed that ≥10%
ischemic myocardium on stress nuclear imaging was associated with a median rate of CAD death
or MI of 4.9%/year (interquartile range: 3.75% to 5.3%). For stress echocardiography, ≥3 newly
dysfunctional segments portend a median rate of CAD death or MI of 4.5%/year (interquartile
range: 3.8% to 5.9%). Although imprecisely delineated, moderate-severe ischemia on cardiac
magnetic resonance may be indicated by ≥4 of 32 stress perfusion defects or ≥3 dobutamine-
induced dysfunctional segments. Risk-based thresholds can define equivalent amounts of ischemia
across the stress imaging modalities, which will help to translate a common understanding of
patient risk on which to guide subsequent management decisions.
Keywords
cardiac imaging; ischemia; prognosis
Stress imaging is commonly used to evaluate suspected myocardial ischemia in patients with
symptoms suggestive of stable ischemic heart disease (SIHD). The evidence to support the
use of several stress imaging modalities is substantial and has been synthesized in recent
appropriate use criteria and clinical practice guidelines (1–3). The published evidence base
for stress nuclear imaging and echo-cardiography as effective tools for diagnosis of coronary
artery disease (CAD) and risk stratification is extensive, and there is growing evidence
supporting the role of stress cardiac magnetic resonance (CMR).
However, the optimal evaluation and treatment algorithm following stress imaging has not
been clearly defined. Although diagnostic coronary angiography is commonly preceded by
stress testing, nearly two-thirds of patients manifest no obstructive CAD at the time of
cardiac catheterization (4,5). Before elective percutaneous coronary intervention (PCI), less
than one-half of patients have had a stress test in the previous 90 days (6). These data
illustrate the lack of accuracy and consistency in clinical practice in the appropriate use of
stress imaging to guide the management of patients with SIHD (1,7,8).
One noteworthy gap in the current evidence base is the absence of established comparable
categories of the magnitude of ischemia across noninvasive imaging modalities. The lack of
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standardized grading and inconsistency in reporting of the extent and severity of ischemia in
clinical practice may contribute to the wide variability in management decisions and high
rates of nonobstructive CAD on diagnostic angiography (5). At a recent Joint Commission/
American Medical Association Quality Summit, the variable reporting of the extent and
severity of ischemia was identified as contributory to the overuse of elective PCI (9). Recent
guidance documents support the requirement of moderate-severe ischemia before elective
PCI (10).
For this report, experts in the field of stress cardiac imaging were enlisted to propose a
consensus of comparable definitions for moderate-severe ischemia for stress nuclear
imaging (myocardial perfusion single-photon emission computed tomography and positron
emission tomography), echocardiography, and CMR (wall motion or perfusion). The cut
points for moderate-severe ischemia were established using the selected, published evidence
for each modality correlating stress imaging results with risk of CAD death or myocardial
infarction (MI). The aim of this review was to propose a definition for equivalent amounts
of ischemia across the stress imaging modalities for patients with SIHD who have preserved
left ventricular function, which will help to translate a common understanding of patient risk
on which to guide subsequent management decisions.
Targeting Moderate-Severe Ischemia
Most SIHD revascularization strategy trials have included patients with ischemia on stress
testing or typical angina with at least 1 coronary stenosis amenable to revascularization,
although only a subset of enrolled patients reported stress test results (11,12). The entry
criteria for the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive
Drug Evaluation) trial ischemia requirements included a minimum of 1 segment with a
perfusion defect or typical ischemic ST-segment changes with exercise (11), resulting in a
representation of patients ranging from those with mild to moderate ischemia on imaging
(13). Given the potential representation of patients with less extensive and severe ischemia
in the COURAGE trial, a lingering question is whether SIHD trial outcomes would have
been different if the COURAGE or National Institutes of Health/National Heart, Lung, and
Blood Institute (NIH/NHLBI)-sponsored BARI 2D (Bypass Angioplasty Revascularization
Investigation in Type 2 Diabetes) trials enrolled a larger proportion of higher-risk patients
with moderate or severe ischemia (11,12). There is limited evidence to guide treatment for
these higher-risk patients.
Figure 1 shows the projected relationship between the underlying abnormal stress imaging
findings and projected CAD events. For stress imaging, the extent of ischemia is directly
related to the rate of subsequent CAD events. Yearly CAD event rates generally range from
~1% for normal stress imaging findings to as high as 10% for severely abnormal studies.
Several observational studies have also shown that the degree of relative risk reduction with
treatment is related to the amount of ischemia observed on noninvasive imaging (14–18).
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Challenges in Uniformly Quantifying Ischemia Across the Stress Imaging
Modalities
A major challenge in defining comparable risk-based thresholds for moderate-severe
ischemia across modalities is that there are notable differences in the various imaging
techniques regarding what is assessed, interpreted, and quantified. Although it is
recommended that all stress imaging techniques use the standardized 17-segment model for
quantification of wall motion and perfusion (19), the 17th segment (i.e., apical cap) is not
separately assessed on stress echocardiography or CMR myocardial perfusion imaging.
There are also differences in the numerical scale used to classify the severity of segmental
perfusion and wall motion abnormalities, with various methods and differences in the ability
to distinguish the subendocardial and subepicardial layers of the myocardium. Nuclear
imaging has several validated quantitative software programs for defining the percentage
ischemic myocardium, including the use of percentage total perfusion defect as used in the
COURAGE trial (20). Given that other modalities interpret ischemic wall motion and
perfusion findings semiquantitatively, this may also introduce differences in the
quantification of the extent and severity of stress-induced abnormalities. These differences
can result in considerable variability in the estimation of the proportion of ischemic
myocardium.
There are additional differences in the ischemic cascade that provide challenges to the
development of comparable definitions of ischemia. Perfusion abnormalities have larger
extent, occur earlier in the ischemic cascade, and are more often associated with
intermediate stenosis, whereas wall motion abnormalities occur later in the ischemic cascade
and are more often associated with more severe stenosis (21). Given the differences in view
orientations across the stress imaging modalities, thresholds that focus on comparing
specific segments (i.e., anterior, lateral) would be problematic. These conceptual differences
may promote a variable relationship between a threshold for moderate-severe ischemia and a
given associated CAD event rate.
Thus, it remains unlikely that absolute thresholds of percentage ischemic myocardium could
be defined similarly across the stress imaging modalities, resulting in the need for an
alternative approach. Therefore, we sought to identify those parameters on each imaging
modality that portend similarly elevated risk levels and to use these to develop comparable
thresholds to guide future care decisions (Fig. 2).
There is an important consideration that risk alone should not be the sole determinant of
defining the potential for therapeutic risk reduction. The purpose of the current review is to
identify comparable risk groups across stress imaging modalities. For some patient subsets,
information on the extent and severity of ischemia must be balanced with correlative
information on the burden of comorbidity and CAD as well as the presence of underlying
left ventricular dysfunction. As such, for our review, we have limited the focus of our
discussion to patients with preserved systolic function.
Because of variable reporting of prognosis by the severity of ischemia, we could not perform
a systematic review. In some cases, data were reported only as survival curves with variable
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follow-up and without inclusion of the number at risk or average duration of follow-up,
included revascularization as an endpoint, reported hazard ratios only, or defined ischemia
as a dichotomous variable (yes/no). For these reasons, we could not systematically collect
clinical outcome data for moderate-severe ischemia and the current review should be
considered a narrative that highlights selected published evidence with available rates of
CAD death or MI in moderate-severe ischemia. Contributing authors also identified
additional data on prognosis with moderate-severe ischemia for the 3 stress imaging
modalities. Importantly, we did not use standardized search terms or independently judge
study quality; this review represents the opinions of the investigators and is not a
systematized synthesis of all available evidence.
The search strategies in MEDLINE included coronary disease prognosis and the specific
imaging modality (stress myocardial perfusion imaging, echocardiography, CMR wall
motion or perfusion imaging). Selected event rates were derived from the published
literature by initially focusing on the rate of CAD death or MI in the nuclear cardiology
literature. We selected a variety of published registry reports with available event data and
follow-up duration in the subset of patients with moderate-severe ischemia. The event data
were obtained from crude rates or reported survival rates. There are several reports on
prognosis from selected registries that report similar event rates by moderate-severe
ischemia. However, we did not include event data from duplicate patient series.
Published Evidence of Elevated Risk Associated With Moderate-Severe
Ischemia
For stress nuclear imaging data, we examined the extensive prognostic evidence reported
from multiple sites, for different radioisotopes, and for positron emission tomography and
single-photon emission computed tomography to define CAD event risk (22). In the nuclear
cardiology literature, a threshold of ≥10% ischemic myocardium has been applied to denote
high-risk status (14–16,22–26). Initial prognostic reports used a summed difference score
(summed stress score – summed rest score) to provide an estimate of the overall magnitude
of ischemia, combining both extent of ischemia (i.e., number of myocardial segments) and
severity (i.e., depth of the defect) (26–29). Recent reports have relied on percentage
myocardium as a summary metric to enhance clinical understanding of the complexity of
findings of ischemia. The percentage ischemic myocardium may be measured using
semiquantitative ([summed difference score/68 (maximal segmental score = 4)] · 100 =
percentage ischemic myocardium) or computer-based quantitative techniques (percentage
ischemic myocardium) (22). There may be variability when using quantitative or
semiquantitative approaches for interpretation such that a threshold of 10% from 1 method
may be slightly higher or lower using an alternative technique. However, in the nuclear
cardiology literature, a threshold of ≥10% of the myocardium has been reported across a
number of prognostic series to denote moderate-severe ischemia (14–16,22–26). For clinical
practice purposes, the risk associated with a threshold of ~10% ischemic myocardium has
been reported and forms the target cut point for our cross-modality estimation of the risk of
CAD death or MI (1,16,22,27,30).
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A review of the published literature reveals that the median rate of CAD death or MI for
patients with ≥10% ischemic myocardium was ~4.9%/year (interquartile range: ~3.7% to
5.3%/year) (Fig. 3) (16,27,30–34). For stress nuclear imaging, the range of CAD event rates
was from as low as 2.3%/year (32) to as high as 6.9%/year (34). These findings of a ~5%
annual CAD event risk are consistent with recent SIHD trials reporting a similar rate of
yearly endpoints (11,12).
Although not derived from the rigors of a clinical trial setting, observational evidence
suggests that the threshold of ≥10% ischemic myocardium may be used as a benchmark
from which to define treatment effectiveness (14–16). Observational evidence indicates that
medical therapy alone is associated with a reduced risk of death as compared with
revascularization for patients with less extensive and severe ischemia (i.e., <10% of the
myocardium); conversely, patients with ≥10% ischemic myocardium had a reduced risk of
CAD and all-cause death with coronary revascularization as compared with medical therapy
(14,15). Selection bias is operational in observational evidence whereby patients with
significant comorbidity would be less likely to undergo revascularization despite their
ischemic risk, thus rendering the comparison of medical therapy and revascularization for
patients with ≥10% ischemia as hypothesis generating. Importantly, in a secondary analysis
of 468 patients in the COURAGE trial with site-interpreted moderate-severe ischemia,
randomization to PCI with optimal medical therapy (OMT) did not result in improved death
or MI-free survival when compared with OMT alone (p = 0.72) (13).
The published research on stress echocardiography commonly indicates that the wall motion
score index includes a very high risk threshold of >1.5 or >1.7 (17,35–39) with an annual
CAD mortality rate of >7% and a significantly elevated hazard for death of 6 (36,37). This
high-risk wall motion score index is rarely observed in clinical practice. We sought to define
clinically useful criteria at a lower level to define a threshold of moderate ischemia.
Applying a threshold of 3 or more ischemic segments, the hazard for CAD events was
elevated ~4-fold when compared with patients with normal stress echo-cardiographic results
(35,40,41). The available evidence using a definition of ≥3 newly dysfunctional segments
revealed an interquartile range from 3.8% to 5.9% (median 4.5%) for annual risk of CAD
death or MI (Fig. 3) (17,35,39,41–49). For stress echocardiography, the CAD event rates
ranged from as low as 2.8%/year (47) to as high as 9.4%/year (45). This result overlaps with
the findings of moderate-severe ischemia with stress nuclear imaging.
A review of the published literature on stress CMR does not reveal consistent documentation
of higher-risk versus lower-risk ischemia but more often a dichotomous reporting of normal/
abnormal or ischemia (yes/no). However, in one report, a subset of very-high-risk patients
with >5 of 16 segments with perfusion defects (including ischemic and fixed) had a risk of a
CAD event of ~14%/year (50). Similarly, a subset of high-risk patients with 2 to 3 vessel
perfusion defects had a hazard ratio that was elevated 4.5-fold to 7.0-fold that of patients
without perfusion defects (51). There are also several patient series reporting that patients
with events had an average of 4 of 16 segments with stress perfusion defects or
dysfunctional segments as compared with <2 abnormal segments for event-free survivors
(50,52,53). Moreover, the unadjusted hazard for CAD death or MI was elevated ~1.2 for
every segment with an ischemic perfusion defect when compared with patients with a
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normal stress perfusion study who have an observed CAD event rate of ~1%/year,
suggesting that patients with >3 ischemic perfusion defects would have an annual risk of
CAD death or MI of ~5% (52,53). A similar relative hazard per ischemic defect or
dysfunctional segment was reported from a larger series of 908 patients undergoing stress
perfusion CMR (54).
Specific data with regard to prognosis associated with dobutamine-induced dysfunctional
segments have been reported. The relative hazard for events was elevated 7.1-fold for 3 to 5
dobutamine-induced wall motion abnormalities when compared with a ~1% event rate for
patients with normal stress CMR (51). Similarly, a relative hazard of 1.2-fold per
dysfunctional segment at stress was reported, which would equate an annual CAD event rate
of ~5% for ≥3 abnormal segments (52,53).
Thus, a reasonable definition for moderate-severe ischemia with stress CMR (annual rate of
CAD death or MI of ~5%) may be ≥4 of 32 stress perfusion defects (≥2 of 16 segments) or
≥3 dobutamine-induced dysfunctional segments (of 16 segments), with CAD event rates
similar to those of stress nuclear imaging and echocardiography.
Although differences exist in interpretation of ischemia across the modalities, the overall
prognostic findings reveal that qualitative or quantitative measures can be defined that
identify overlap in the annual rates of CAD death or MI of ~5%/year (Fig. 4). It remains
likely that the threshold requirement of moderate-severe ischemia may allow for greater
harmonization in the estimated risk of CAD events in patients with SIHD.
Consideration of Ancillary High-Risk Markers
We considered revising the criteria for moderate-severe ischemia by including additional
high-risk qualifiers using left ventricular function or volume measurements in addition to
other modality-specific measures (such as strain, scarring, edema, or transient ischemic
dilation of the left ventricle). There is added value when multiple parameters are combined
during the same scan. For example, the presence or absence of myocardial scarring or edema
assessed during the same scan adds to the information derived from perfusion and wall
motion analyses (55). Data on the impact of combining these markers on prognosis and
therapeutic decision making and outcome, however, are lacking. Our proposed criteria do
not distinguish exercise and pharmacological stress and do not incorporate patient clinical
risk or functional capabilities that would affect the anticipated risk of CAD events.
There was considerable discussion about the use of imaging-based criteria alone without
inclusion of ancillary markers. One argument was put forth that simpler is better. The Duke
Treadmill Score integrates 3 parameters into an estimation of 5-year CAD mortality (56).
Although additional exercise parameters have been reported in the peer-reviewed literature,
the novelty of the Duke Treadmill Score is its parsimony and ease of use. Ultimately, it was
believed that the use of a simple criterion would be more reliably applied in clinical practice
and the data regarding prognosis are less robust when additional factors are included.
Ideally, this report could serve as the starting point for the establishment of stress imaging
criteria to be applied clinically. This would then form the basis for further revisions that may
refine and integrate important clinical and stress parameters that improve the precision of
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CAD risk estimates and the generalizability of the findings to varying patient subsets.
Importantly, clinicians should use our thresholds as an initial guide to estimated risk.
Inclusion of additional clinical, stress testing, or imaging parameters may further refine
estimates for the individual patient.
Study limitations
The extent to which we cannot consistently identify the prognosis of moderate-severe
ischemia from the published literature exemplifies the limitations of our current knowledge.
The development of more quantitative methods for determining perfusion defect or
dysfunctional segmental analysis could help define risk and guide decisions about treatment.
Moreover, the development of easily defined categories of risk may further promote quality-
based treatment and performance metrics for laboratory standards. The prognostic
significance of noninvasive testing differs on the basis of the population in which it is
applied. For example, the risk in younger or exercising patients differs from that of older or
functionally impaired patients. The prevalence of prior MI or revascularization can also alter
the CAD event risk estimates. We attempted to narrow the width of expected CAD event
rates by focusing on patients with SIHD who had moderate-severe ischemia and preserved
left ventricular function. The sample size and length of follow-up would further contribute
variability to the CAD risk estimates. The smaller sample sizes for stress echocardiography
and CMR (e.g., median sample sizes of 1,737 and 503, respectively) may add variability to
the CAD event rates when compared with the larger stress nuclear series (median sample
size: 5,845).
There are also challenges in the reproducibility of physician-interpreted moderate-severe
ischemia (57). Reproducibility is affected by reader expertise, equipment, image quality, and
other factors. We anticipate greater variability in the reproducibility of moderate-severe
ischemia when a subjective interpretation is used.
Historically, varied analytical approaches have been applied in prognostic series to handle
the subsets of patients who undergo coronary revascularization during follow-up. Patients
who undergo early revascularization (e.g., ≤90 days) are excluded from analysis in some
cases but are censored at the time of the procedure in other cases (28,43). The rationale for
the censoring of patients who undergo early revascularization is that the procedure is
believed to affect CAD survival. In this case, the CAD event rates reflect a medical strategy.
More recent series do not use this method of censoring for revascularization because recent
trials failed to show a clinical benefit from coronary revascularization when compared with
OMT (11,12).
Importantly, these factors influence the precision of our estimate. However, we believe that
the attempt to impose rigor in the field of stress CAD imaging can prompt a greater
emphasis on standardized approaches to image interpretation. We propose comparable risk-
based definitions for moderate-severe ischemia that may help to translate a common
understanding of patient risk on which to guide subsequent management decisions. Our
definitions are formed on the basis of a number of assumptions, including that the stress
imaging protocols, interpretation, and reporting are consistent with imaging society
standards.
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Future Comparative Trial Evidence
In 2012, the NIH/NHLBI-sponsored ISCHEMIA (International Study of Comparative
Health Effectiveness With Medical and Invasive Approaches) trial began enrolling patients
with moderate-severe ischemia on stress nuclear imaging, echocardiography, or CMR. The
ISCHEMIA eligibility criteria for moderate-severe ischemia are detailed in Table 1 and
correspond to those discussed in this report. The primary aim of the ISCHEMIA trial is to
test the hypothesis that among patients with moderate-severe ischemia on stress imaging, a
routine early invasive strategy with coronary angiography followed by optimal
revascularization plus OMT is superior to an initial conservative strategy of OMT alone,
with angiography and revascularization reserved for those who fail to respond to medical
therapy. The primary endpoint is a composite of incident cardiovascular death or MI over ~4
years of follow-up. The ISCHEMIA trial will aid in identifying patients who may benefit
from coronary angiography and revascularization, with the trial results affecting the lives of
the nearly 10 million patients who undergo stress imaging each year.
Current evidence indicates that substantial equipoise exists with regard to the decision to
refer a patient for coronary angiography, despite the common belief to the contrary in the
cardiology community. On the basis of 9 published reports from 51 sites (N = 5,833), the
rate of referral from stress nuclear imaging to coronary angiography in patients with
moderate-severe ischemia was only 35% to 65% (58–66). Contemporary data from the NIH/
NHLBI SPARC (Study of Myocardial Perfusion and Coronary Anatomy Imaging Roles in
CAD), a 40-center multimodality registry of 3,019 patients enrolled between 2006 and 2008,
revealed that only 42% of patients with moderate-severe ischemia were referred for
coronary angiography (63).
Conclusions
On the basis of a selected review of the published literature, comparable CAD event rates
(rate of CAD death or MI of ~5%/year) for patients with SIHD who have moderate-severe
ischemia can be identified for those undergoing stress nuclear imaging, echocardiography,
or CMR. An example of each of the imaging modalities using the proposed definition for
moderate-severe ischemia is illustrated in Figure 5 (see Online Videos 1, 2, 3, and 4 for
stress echocardiography example). Defining comparable risk-based thresholds for moderate-
severe ischemia across the different stress imaging modalities will help to translate a
common understanding of patient risk and guide management decisions. These risk-based
thresholds should be applied only when standardized protocols and interpretation are used
during stress imaging. Definitive guidance on the therapeutic effectiveness of an
angiographic-guided strategy for patients with moderate-severe ischemia will be derived
from ongoing clinical trials, such as the ISCHEMIA trial.
Moreover, we put forth a simple criterion that we believe could be easily applied in clinical
practice. We also identified limitations to the development of comparable definitions. We
hope that this report will serve as a starting point and that further revisions will ensue to
improve the precision of the CAD risk estimate and the generalizability of the findings to
varying patient subsets.
Shaw et al. Page 9
JACC Cardiovasc Imaging. Author manuscript; available in PMC 2015 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
The authors thank Dr. Raymond Gibbons for his careful review and comments on this manuscript.
Dr. Shaw has received research support from Astellas and Bracco Diagnostics Inc. Dr. Friedrich is a board member,
advisor, and shareholder for Circle Cardiovascular Imaging. Dr. Senior is a member of the speaker’s bureau for and
has received honoraria from Bracco Diagnostics Inc. and Philips Healthcare. Dr. Min is a member of the medical
advisory board and speaker’s bureau for and has received research support from GE Healthcare; is a member of the
medical advisory board for Arineta Ltd.; has received research support from Philips Healthcare; and holds equity
interest in TC3 and MDDX. Dr. Arai has received research support from Siemens. Dr. Iskandrian is a member of
the advisory committee for Rapidscan Pharma. Dr. Bateman is a member of the advisory committee for and
receives research support from Astellas, Lantheus Medical Imaging, GE Healthcare, and Spectrum Dynamics. Dr.
Miller is a consultant for Astellas. Dr. Nagel has received research support from Philips Healthcare and Bayer
HealthCare. Dr. Borges-Neto is a member of the speaker’s bureau and advisory board for and has received grant
support from Astellas and is a member of the advisory board for and has received grant support from GE
Healthcare. Dr. Hochman has received a consulting fee and modest honoraria from GlaxoSmithKline.
ABBREVIATIONS AND ACRONYMS
CAD coronary artery disease
CMR cardiac magnetic resonance
MI myocardial infarction
NHLBI National Heart, Lung, and Blood Institute
NIH National Institutes of Health
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Figure 1. Projected CAD Event Rates
A theoretical plot of the relationship between abnormal stress imaging findings and
projected CAD events is shown. The lines include the average projected CAD event rate and
95% confidence intervals. As the stress imaging abnormalities become more extensive and
severe, the projected CAD event rate increases. Conversely, for subsets with normal or
mildly abnormal studies, the event rates are low. CAD = coronary artery disease.
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Figure 2. Risk-Based Comparisons
A theoretical approach to comparing levels of moderate-severe ischemia across the stress
imaging modalities is used to define similar CAD event rates. Abbreviation as in Figure 1.
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Figure 3. Risk of CAD Death or MI for Moderate-Severe Ischemia
The median rates of CAD death or MI (%/year) on the basis of moderate-severe ischemia on
stress nuclear myocardial perfusion imaging and stress echocardiography are shown. This
narrative review highlights selected published evidence of rates of CAD death or MI for
stress nuclear imaging and echocardiography; the dashed lines show the interquartile range
of the CAD event rates (per year). The expected rate of CAD death or MI across all of the
stress imaging modalities is ~4% to 6%/year. There are limitations to our median estimate,
including that this was not a systematic review because of differential sample size, variable
length of follow-up, and the use of mortality only or revascularization as an endpoint. MI =
myocardial infarction; other abbreviation as in Figure 1.
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Figure 4. Definitions of Moderate-Severe Ischemia
Comparable multimodality estimates of moderate-severe ischemia using risk-based
thresholds of CAD death or MI rates of 4% to 6%/year. CMR = cardiac magnetic resonance;
other abbreviations as in Figures 1 and 3.
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Figure 5. Case Examples
(A) (i) Illustrative case of moderate ischemia with stress myocardial perfusion SPECT.
Regadenoson stress (upper rows)/rest (lower rows) Tc-99m sestamibi SPECT images show
moderate reduction of perfusion in the distal, mid, and basal inferior wall. Semiquantitative
visual analysis (lower right polar maps) reveals 3 abnormal segments at stress with a total
score of 7 and normal rest scores. The summed difference score is 7, representing 10% of
the myocardium. (ii) Quantitative analysis of the case shown in i. Stress polar maps (middle
column) reveal a perfusion defect (black area) on stress images (top) and normal rest
images (middle). The TPD at stress is 11% and at rest is zero, indicating an ischemic TPD
of 11%. (B) Illustrative case of moderate ischemia with stress echocardiography. Apical
views from an exercise stress echocardiogram show moderate ischemia. Regional wall
motion is normal at rest. At peak stress, wall motion abnormalities (severe hypokinesis) are
observed in 3 segments: mid anterior, apical anterior, and apical lateral segments (arrows).
See Online Videos 1, 2, 3, and 4. (C) Illustrative case of moderate ischemia with stress
cardiac magnetic resonance perfusion imaging. The top row shows stress perfusion
imaging, and the bottom row shows late gadolinium enhancement imaging of infarction. In
both rows, basal short-axis locations are on the left, mid short-axis locations are in the
middle, and distal short-axis locations are on the right. Note the spatial extent of the stress
perfusion defect involving the basal anteroseptal (subendocardial) and inferoseptal
(subendocardial and subepicardial), mid anteroseptal (subendocardial and subepicardial),
and distal septal (subendocardial and subepicardial) walls. There are 7 subsegments of 32
demonstrated abnormal stress perfusion defects. None of these subsegments demonstrated
evidence of infarction by late gadolinium enhancement imaging. This case illustrates a
patient with moderate ischemia without infarction in the left anterior descending territory.
SPECT = single-photon emission computed tomography; TPD = total perfusion deficit.
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Table 1
National Institutes of Health/National Heart, Lung, and Blood Institute–Sponsored ISCHEMIA Trial Criteria
for Moderate-Severe Ischemia
Nuclear Perfusion Echocardiographic Wall Motion
Cardiac Magnetic Resonance Perfusion or Wall
Motion
≥10% ischemic myocardium ≥3 of 16 segments with stress-induced hypokinesis
or akinesis*
≥4 of 32 stress perfusion defects (≥2 of 16 segments) or
≥3 dobutamine-induced dysfunctional segments (out of
16 segments)
*
The one exception to the characterization of ischemic wall motion change is that when segments change from akinetic to dyskinetic during stress
in the absence of demonstration of a biphasic response, this is considered a nonspecific response rather than an ischemic response.
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